Get the Stockscreener App
245.01
2.44%
-6.14
After Hours:
245.01
Bio Rad Laboratories Inc stock is traded at $245.01, with a volume of 195.13K.
It is down -2.44% in the last 24 hours and down -20.03% over the past month.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (56% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (44% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (42% of 2023 sales), Europe (31%), Asia (31%), and other (6%). Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
See More
Previous Close:
$251.15
Open:
$249.29
24h Volume:
195.13K
Relative Volume:
0.89
Market Cap:
$6.86B
Revenue:
$2.58B
Net Income/Loss:
$-778.69M
P/E Ratio:
-8.9649
EPS:
-27.33
Net Cash Flow:
$223.75M
1W Performance:
-5.02%
1M Performance:
-20.03%
6M Performance:
-24.89%
1Y Performance:
-27.17%
1-Day Range:
$244.00
$250.94
1-Week Range:
$244.00
$263.88
52-Week Range:
$244.00
$387.99
Bio Rad Laboratories Inc Stock (BIO) Company Profile
Name
Bio Rad Laboratories Inc
Sector
Industry
Phone
(510) 724-7000
Address
1000 ALFRED NOBEL DRIVE, HERCULES
Compare BIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIO
Bio Rad Laboratories Inc
|
245.01 | 6.86B | 2.58B | -778.69M | 223.75M | -27.33 |
|
ABT
Abbott Laboratories
|
129.89 | 225.27B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
95.37 | 140.74B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
363.66 | 138.77B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
92.33 | 118.39B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
67.95 | 39.95B | 5.72B | 4.17B | 259.90M | 6.97 |
Bio Rad Laboratories Inc Stock (BIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-01-24 | Upgrade | Citigroup | Neutral → Buy |
| Aug-28-24 | Initiated | Wells Fargo | Equal Weight |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Apr-03-24 | Downgrade | Citigroup | Buy → Neutral |
| Dec-07-23 | Initiated | UBS | Buy |
| Jun-16-23 | Initiated | Wells Fargo | Overweight |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jan-28-22 | Reiterated | Citigroup | Buy |
| Jan-08-20 | Initiated | Wells Fargo | Overweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Oct-17-18 | Initiated | Goldman | Buy |
| Sep-20-18 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-16-18 | Downgrade | CL King | Buy → Neutral |
| Jul-13-17 | Initiated | Wells Fargo | Outperform |
| Jun-28-17 | Upgrade | Deutsche Bank | Hold → Buy |
| Jan-18-17 | Initiated | Deutsche Bank | Hold |
| Oct-13-16 | Initiated | CL King | Buy |
| May-06-15 | Reiterated | Jefferies | Buy |
| Dec-18-09 | Initiated | Maxim Group | Buy |
| Nov-06-09 | Initiated | Jefferies & Co | Buy |
| Jul-17-09 | Initiated | Soleil | Buy |
| Sep-26-07 | Initiated | Banc of America Sec | Buy |
| Feb-23-07 | Downgrade | Robert W. Baird | Outperform → Neutral |
View All
Bio Rad Laboratories Inc Stock (BIO) Latest News
New XP-Design Assay Salmonella Serotyping Solution for Rapid, Accurate Food Safety Testing - Food Safety Magazine
Newborn Screening Market Growth in Future Scope 2025-2032 | - openPR
Charles Schwab Investment Management Inc. Boosts Position in Bio-Rad Laboratories, Inc. (NYSE:BIO) - Defense World
Laboratory Supplies Market Generated Opportunities, Future - openPR
Complement C4 Antibody Market Research 2025: Growing Focus on Precision Medicine and Targeted Therapies, and Increasing Investment in Immunotherapies and Biologic Drugs - GlobeNewswire Inc.
ChemiDoc Go Imaging System - The Scientist
HIV Rapid Test Kits Market Focused Insights 2025-2030: Abbott, Bio-Rad, and bioMerieux Strengthen Market Position Amid Rising Competition - Yahoo Finance
Stem Cell Assay Market Demand, Industry Growth and Future Scope - openPR
Empowering Growth: Vector Purification Market 2025 - openPR
Clinical Biomarkers Market Key Players Analysis- Johnson & - openPR
Expanded kit range enhances AAV vector characterisation - Labmate Online
Neurological Biomarkers: Global Market Review 2020-2024 and - GlobeNewswire
High-Performance Liquid Chromatography Market Top Players - openPR
Genomics Market Expansion | Future Trends & Investment Insights - openPR
Bio-Rad stock touches 52-week low at $248.05 amid market shifts By Investing.com - Investing.com South Africa
Bio-Rad stock touches 52-week low at $248.05 amid market shifts - Investing.com Canada
Cancer Monoclonal Antibodies Market Is Booming Worldwide | Abnova Corporation, BioGenex, Bio-Rad Laboratories - openPR
Blood Cancer Diagnostics Market Analysis Report 2025-2030, with Quest Diagnostics, Illumina, InVivoScribe, Asuragen, Danaher, Sequenta, SkylineDx, Bio-Rad Laboratories, Alercell & Sophia Genetics - Yahoo Finance
Zacks Research Has Negative Outlook of BIO Q1 Earnings - Defense World
Proteomics Market Projected To Witness Substantial Growth, 2025-2032: Bio-Rad Laboratories, Inc., GE - EIN News
Zacks Research Issues Pessimistic Outlook for BIO Earnings - Defense World
Bio-Rad Laboratories, Inc. (NYSE:BIO) is a favorite amongst institutional investors who own 60% - Yahoo Finance
Japan In-Vitro Diagnostics Market Forecast Report and - GlobeNewswire
Japan In-Vitro Diagnostics Market Forecast Report and Company Analysis 2025-2033 Featuring Abbott, Danaher, Biomerieux, Roche, Becton, Sysmex, Bio-Rad Laboratories, Thermofisher Scientific - Yahoo Finance
Bio-Rad Laboratories, Inc. Class A to Host Earnings Call - ACCESS Newswire
Protein A Resin Market: Growth, Trends, Key Players, - openPR
How to Take Advantage of moves in (BIO.B) - Stock Traders Daily
Cancer Biomarkers Research Report 2024: Global Market Projected to Soar to USD 62.14 Billion by 2034, Driven by Technological Advancements and Increasing Demand for Early Detection - GlobeNewswire Inc.
Polyclonal Antibody Market Growth: Impact on Healthcare & - openPR
Protein Chip Market Detailed In New Research Report 2025 | Agilent Technologies, PerkinElmer, Bio-Rad Laboratories - openPR
Is Bio-Rad Laboratories, Inc. (BIO) the Best Medical Technology Stock to Buy According to Analysts? - Insider Monkey
Life Science Products Market Detailed In New Research Report - openPR
High-Throughput Screening Technology Analysis and Global - GlobeNewswire
High-Throughput Screening Technology Analysis and Global Markets 2021-2024 & 2025-2029 with Danaher, Thermo Fisher Scientific., Charles River Laboratories, Revvity and Bio-Rad Laboratories Leading - Yahoo Finance
Bay Area biotech giant Bio-Rad to lay off hundreds after $1.8 billion loss - MSN
Bio-Rad Laboratories, Inc. (NYSE:BIO) Stock Holdings Lessened by Hosking Partners LLP - MarketBeat
Bio-Rad Laboratories, Inc. (NYSE:BIO) Shares Sold by Veritas Asset Management LLP - MarketBeat
Blackhawk Capital Partners LLC. Purchases 1,427 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) - MarketBeat
Fjarde AP Fonden Fourth Swedish National Pension Fund Purchases 1,200 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) - MarketBeat
New York State Common Retirement Fund Sells 1,000 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) - Defense World
7 Best Medical Technology Stocks To Buy According To Analysts - Insider Monkey
Bio-Rad stock touches 52-week low at $262.11 amid market shifts - Investing.com
Tech, life science companies slash hundreds more Bay Area workers - MSN
Some Confidence Is Lacking In Bio-Rad Laboratories, Inc. (NYSE:BIO) As Shares Slide 28% - Simply Wall St
Analyzing the Potential $677 Million Expression Vectors - GlobeNewswire
Principal Financial Group Inc. Sells 234 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) - Defense World
Sample Preparation Market Key Players AnalysisMerck KgaA, - openPR
Minimal Residual Disease Testing Market Expanding with - openPR
Bio-Rad (BIO) International Revenue Performance Explored - Yahoo Finance
Truist Financial Corp Purchases 72 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) - Defense World
Venturi Wealth Management LLC Raises Position in Bio-Rad Laboratories, Inc. (NYSE:BIO) - Defense World
Bio Rad Laboratories Inc Stock (BIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.40%
0.89%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):